Human Immunodeficiency Virus (HIV)

Immunology·MeSH: Acquired Immunodeficiency Syndrome

9 drugs in development·4 companies·3 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
Doravirine	Merck & Co., Inc. (MRK)
Emtricitabine/tenofovir disoproxil	Merck & Co., Inc. (MRK)
MK-8527	Merck & Co., Inc. (MRK)

Phase 2(2)

Drug	Company
2 NRTIs	Merck & Co., Inc. (MRK)
DOR/3TC/TDF	Merck & Co., Inc. (MRK)

Phase 1(2)

Drug	Company
hb-500	HOOKIPA Pharma Inc. (HOOK)
hb-502	HOOKIPA Pharma Inc. (HOOK)

Phase 1/Phase 2(1)

Drug	Company
IMC-M113V	Immunocore Holdings plc (IMCR)

Phase 2/Phase 3(1)

Drug	Company
PRO 140	CytoDyn Inc. (CYDY)

BioSniper tracks 9 drugs in development for Human Immunodeficiency Virus (HIV) across 4 companies.

There are 3 clinical trials targeting Human Immunodeficiency Virus (HIV) tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.